Stocks of anti-obesity drugmakers Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN) have gotten hit as the market frets over what a Robert F. Kennedy Jr.-run Department of Health and Human Services would mean for the group. The worries are overblown, and investors should use the selloff to scoop the stocks up on the cheap, Jacob Sonenshine writes in this week’s edition of Barron’s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Sanofi (SNY) Is Seeking to Change How It Gives Discounts to Hospitals
- Sanofi planning changes to 340B hospital drug discount plan, WSJ reports
- Protagonist Therapeutics price target raised to $67 from $51 at BTIG
- HIMS Stock Surges after Court Case with Eli Lilly Gets Put on Hold
- FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi